ReveraGen BioPharma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.reveragen.com
A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT05166109
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇮🇹Azienda Ospedale Universita Padova, Padova, Italy
Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Registration Number
- NCT04348890
A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT03439670
- Locations
- 🇨🇦
Montreal Children's Hospital, Montréal, Quebec, Canada
🇧🇪Ghent University Hospital, Ghent, Belgium
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Interventions
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT03038399
- Locations
- 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸Nemours Children's Hospital, Orlando, Florida, United States
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02760277
- Locations
- 🇺🇸
University of California Davis, Davis, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Nemours Children's Hospital, Orlando, Florida, United States
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02760264
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇦🇺Sydney Children's Hospital, Westmead, Australia
A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- ReveraGen BioPharma, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT02415439
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States